SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
- Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
- Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
- Orthobiologics revenue growth driven by new products such as OsteoStrand Plus
- Ex-U.S. revenue grew 14.5%, primarily on the strength of Europe
Segment sales and growth on an as-reported basis:
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Spine | $17.1 | $15.2 | $2.0 | 13.0% |
| Orthobiologics | $19.0 | $18.0 | $1.0 | 5.6% |
| Total | $36.2 | $33.2 | $3.0 | 9.0% |
Revenue by geographic region:
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $32.0 | $29.5 | $2.4 | 8.3% |
| Ex-US | $4.2 | $3.6 | $0.5 | 14.5% |
| Total | $36.2 | $33.2 | $3.0 | 9.0% |
Net earnings:
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $36.2 | |
| Cost of Sales | -$13.6 | 37.6% |
| Other | -$0.74 | 2.0% |
| R & D | -$3.5 | 9.7% |
| Selling and Admin | -$27.3 | 75.5% |
| Net Earnings | -$9.0 | -24.9% |
Sources: SeaSpine
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
Orthobiologics...
SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
- Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
- Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
- Orthobiologics revenue growth driven by new products such as OsteoStrand Plus
- Ex-U.S. revenue grew 14.5%, primarily on the strength of Europe
Segment sales and growth on an as-reported basis:
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Spine | $17.1 | $15.2 | $2.0 | 13.0% |
| Orthobiologics | $19.0 | $18.0 | $1.0 | 5.6% |
| Total | $36.2 | $33.2 | $3.0 | 9.0% |
Revenue by geographic region:
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $32.0 | $29.5 | $2.4 | 8.3% |
| Ex-US | $4.2 | $3.6 | $0.5 | 14.5% |
| Total | $36.2 | $33.2 | $3.0 | 9.0% |
Net earnings:
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $36.2 | |
| Cost of Sales | -$13.6 | 37.6% |
| Other | -$0.74 | 2.0% |
| R & D | -$3.5 | 9.7% |
| Selling and Admin | -$27.3 | 75.5% |
| Net Earnings | -$9.0 | -24.9% |
Sources: SeaSpine
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





